JavaScript is NOT enabled !

* Show help

1 hits in Medvik Filters

Article

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

Quesada, Stanislas
Author Quesada, Stanislas Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France Department of Cancer Genetics, University Hospital of Montpellier, Montpellier, France Groupe d'Investigateurs Nationaux pour l'Etude des cancers de l'ovaire et du sein (GINECO), Paris, France Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France
Penault-Llorca, Frédérique
Author Penault-Llorca, Frédérique Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France Department of Biology and Pathology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR 1240 INSERM-UCA, Clermont-Ferrand, France Cours St Paul, Saint Paul, Réunion, France
Matias-Guiu, Xavier
Author Matias-Guiu, Xavier Department of Pathology, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, University of Lleida, Lleida, Spain Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain European Society of Pathology (ESP), Belgium
Banerjee, Susana
Author Banerjee, Susana The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
Barberis, Massimo
Author Barberis, Massimo Division of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy
Coleman, Robert L
Author Coleman, Robert L Texas Oncology, US Oncology Network, The Woodlands, TX, USA
Colombo, Nicoletta
Author Colombo, Nicoletta Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy
DeFazio, Anna
Author DeFazio, Anna Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
McNeish, Iain A
Author McNeish, Iain A Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London, London, UK
Nogueira-Rodrigues, Angélica
Author Nogueira-Rodrigues, Angélica Federal University MG, Brazilian Group of Gynecologic Oncology (EVA), Latin American Cooperative Oncology Group (LACOG), Oncoclínicas, DOM Oncologia, Brazil

European journal of cancer. 2025 ; 215 (-) : 115169. [pub] 20241209

Eur J Cancer
ISSN 1879-0852
Medvik
Source

BACKGROUND: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the optimal HRD testing strategy is an area of debate. Moreover, recently published clinical and translational data may impact how HRD status may be used to identify patients likely to benefit from PARPi use. We aimed to extensively compare available HRD CDx and establish a worldwide expert consensus on HRD testing in primary and recurrent OC. METHODS: A group of 99 global experts from 31 different countries was formed. Using a modified Delphi process, the experts aimed to establish consensus statements based on a systematic literature search and CDx information sought from investigators, companies and/or publications. RESULTS: Technical information, including analytical and clinical validation, were obtained from 14 of 15 available HRD CDx (7 academic; 7 commercial). Consensus was reached on 36 statements encompassing the following topics: 1) the predictive impact of HRD status on PARPi use in primary and recurrent OC; 2) analytical and clinical validation requirements of HRD CDx; 3) resource-stratified HRD testing; and 4) how future CDx may include additional approaches to help address unmet testing needs. CONCLUSION: This manuscript provides detailed information on currently available HRD CDx and up-to-date guidance from global experts on HRD testing in patients with primary and recurrent OC.

MeSH
Delphi Technique MeSH
Homologous Recombination MeSH
Consensus * MeSH
Humans MeSH
Biomarkers, Tumor genetics MeSH
Ovarian Neoplasms * genetics diagnosis drug therapy MeSH
Poly(ADP-ribose) Polymerase Inhibitors * therapeutic use MeSH
Check Tag
Humans MeSH
Female MeSH
Publication type
Journal Article MeSH
Comparative Study MeSH

Collections

Published

Filters

* Show help

* Show help

Refine by MeSH